The immunogram of inflammatory breast cancer
Inflammatory breast cancer (IBC) is the most aggressive clinical presentation of breast cancer (BC) and accounts for 2-4% of all new cases [1]. The treatment of non-metastatic IBC includes standard neoadjuvant therapy, surgery and radiotherapy. Instead, patients with metastatic IBC are treated with systemic therapy regimens not dissimilar to the treatments used for non-IBC[2]. The improvement of median overall survival (OS) of patients with localized IBC, to nearly 4 years with multimodality treatment, is still unsatisfying and tremendous efforts are required to improve the poor outcomes of this fatal form of BC [3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Carmine Valenza, Dario Trapani, Nicola Fusco, Xiaoping Wang, Massimo Cristofanilli, Naoto T. Ueno, Giuseppe Curigliano Tags: Anti-tumour Treatment Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Inflammatory Breast Cancer | Neoadjuvant Therapy